Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entocort EC safety study in pediatric Crohn's disease
2011-003743-22Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of budesonide in Crohn's disease (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety. Started Oct 2011; status: completed.
02
Drugs
budesonide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-003743-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003743-22.